Mirdametinib + BGB-3245 in Advanced Solid Tumors
Stopped early · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor
In brief
A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate targeted therapy, or for which there is no treatment available, or prior standard of care therapy was not tolerated.
Key facts
- Study ID
- NCT05580770
- Run by
- SpringWorks Therapeutics, Inc.
- People needed
- 23
- Starts
- 2023-02-03
- Expected to finish
- 2025-01-15
- Last updated by the study team
- 2026-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UC San Diego Moores Cancer Center — La Jolla, California, United States
- Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
- Calvary Mater Newcastle — Waratah, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.